Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229956 | 1.00 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL24878606 | 1.00 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL26535949 | 1.00 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL29195406 | 1.00 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL13715722 | 0.96 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL3915198 | 0.96 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL6928627 | 0.95 | P2RY6 (0.40) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL6518721 | 0.94 | TYMP (0.35) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL16214972 | 0.94 | TYMP (0.35) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL668064 | 0.94 | TYMP (0.35) | TYMPP2RY6P2RY14NT5EP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206389-A | Multivalent ligand clusters for targeted delivery of therapeutic agents | 有丝分裂疗法有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-2647713-B1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| EP-2899278-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20150011608-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| EP-2636739-B1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS INC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2647713-A1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
| EP-2636739-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120045461-A1 | Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAs | ALNYLAM PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110224282-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2365077-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8003619-B2 | Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| US-7947659-B2 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7919473-B2 | IRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20060223770-A1 | IRNA agents targeting VEGF | ALNYLAM EUROPE AG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060094032-A1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094032-A1 | iRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885P2RY6 4719/4885P2RY14 4836/4885 |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | POLM, POLN, PNKP | TYMP 15/4885P2RY6 1762/4885P2RY14 2450/4885 |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | NSUN2, TRDMT1, POLRMT | TYMP 151/4885P2RY6 3959/4885P2RY14 4177/4885 |
| US-20060223770-A1 | IRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885P2RY6 4719/4885P2RY14 4836/4885 |
| US-20110224282-A1 | iRNA Agents Targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885P2RY6 4719/4885P2RY14 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.